aTyr Pharma (LIFE) Misses Q1 EPS by 19c

aTyr Pharma (NASDAQ: LIFE) reported Q1 EPS of ($0.51), $0.19 worse than the analyst estimate of ($0.32).

“During the first quarter, we remained focused on advancing our lead therapeutic candidate, ATYR1923. We are tracking towards the readout from our Phase 1b/2a proof-of-concept study in pulmonary sarcoidosis, our initial interstitial lung disease (ILD) indication, which is expected in the third quarter of this year,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “We have key mechanistic insights regarding ATYR1923’s anti-inflammatory effects in patients from our Phase 2 study in COVID-19 related respiratory complications. This clinical data is consistent with what we have seen preclinically for key anti-inflammatory cytokines that are implicated in sarcoidosis and other ILD.”

“Furthermore, we generated additional preclinical data for ATYR2810, our lead anti-Neuropilin-2 (NRP2) antibody and IND candidate, including research presented at the American Academy of Cancer Research (AACR) Annual Meeting demonstrating tumor inhibitory effects in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC), as both a single agent and in combination with chemotherapy and the targeted agent bevacizumab. Our manufacturing agreement with Lonza for the production of this antibody reflects our commitment to this program. We are off to a strong start in 2021 and look forward to building upon this progress throughout the year.”

For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.

You May Also Be Interested In

• Sanuwave Q2 2026 revenue tops revised guidance range
• Trex raises 2026 guidance, names SBP as sole national distributor
• MBX Biosciences names new CEO and CFO amid leadership shift